Saturable absorption of sorafenib in patients with solid tumors: A population model

Investigational New Drugs

Volumn 30, Issue 5, 2012, Pages 1991-2000

  Hornecker, Marilyne ^a   Blanchet, Benoit ^a,b   Billemont, Bertrand ^a,b   Sassi, Hind ^a   Ropert, Stanislas ^a,b   Taieb, Fabrice ^a   Mir, Olivier ^a,b,c   Abbas, Halim ^a   Harcouet, Laura ^a   Coriat, Romain ^a,b,c   Dauphin, Alain ^a   Goldwasser, François ^a,b,c   Tod, Michel ^d,e  

^a Hôpital Cochin ^*  (France)

^b Centre d étude et de recours sur les inhibiteurs de l angiogénèse CERIA   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d CROIX ROUSSE HOSPITAL   (France)

^e UNIVERSITÉ DE LYON   (France)

Author keywords

Absorption saturation; Dosing regimen; Population pharmacokinetics; Sorafenib

Indexed keywords

ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CHOLESTEROL; CREATININE; NITROGEN; SORAFENIB; UREA;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HUMAN; KIDNEY CARCINOMA; LIMIT OF QUANTITATION; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SOLID TUMOR; STEADY STATE; THYROID CANCER; TIME TO MAXIMUM PLASMA CONCENTRATION; UREA BLOOD LEVEL;

ABSORPTION; ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL AVAILABILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NEOPLASMS; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; YOUNG ADULT;

EID: 84867846879     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-011-9760-z     Document Type: Article

References (26)

1. Carlomagno F, Anaganti S, Guida T, Salvatore G, Troncone G, Wilhelm SM, Santoro M (2006) BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 98(5):326-334
2. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64(19):7099-7109
3. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M (2008) Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 7(10):3129-3140
4. Takimoto CH, Awada A (2008) Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trials. Cancer Chemother Pharmacol 61(4):535-548
5. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, Negrier S, Chevreau C, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Anderson S, Hofilena G, Shan M, Pena C, Lathia C, Bukowski RM (2009) Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 27(20):3312-3318
6. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378-390
7. Blanchet B, Billemont B, Barete S, Garrigue H, Cabanes L, Coriat R, Frances C, Knebelmann B, Goldwasser F (2010) Toxicity of sorafenib: clinical and molecular aspects. Expert Opin Drug Saf 9(2):275-287
8. European Medicines Agency Sorafenib (Nexavar): summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/ humandocs/PDFs/EPAR/nexavar/H-690-PI-en.pdf.
9. Awada A, Hendlisz A, Gil T, Bartholomeus S, Mano M, de Valeriola D, Strumberg D, Brendel E, Haase CG, Schwartz B, Piccart M (2005) Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 92(10):1855-1861
10. Moore M, Hirte HW, Siu L, Oza A, Hotte SJ, Petrenciuc O, Cihon F, Lathia C, Schwartz B (2005) Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 16(10):1688-1694
11. Minami H, Kawada K, Ebi H, Kitagawa K, Kim YI, Araki K, Mukai H, Tahara M, Nakajima H, Nakajima K (2008) Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors. Cancer Sci:1492-1498
12. Miller AA, Murry DJ, Owzar K, Hollis DR, Kennedy EB, Abou-Alfa G, Desai A, Hwang J, Villalona-Calero MA, Dees EC, Lewis LD, Fakih MG, Edelman MJ, Millard F, Frank RC, Hohl RJ, Ratain MJ (2009) Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol 27(11):1800-1805
13. Furuse J, Ishii H, Nakachi K, Suzuki E, Shimizu S, Nakajima K (2008) Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci 99(1):159-165
14. Clark JW, Eder JP, Ryan D, Lathia C, Lenz HJ (2005) Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 11(15):5472-5480
15. Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, Faghih M, Brendel E, Voliotis D, Haase CG, Schwartz B, Awada A, Voigtmann R, Scheulen ME, Seeber S (2005) Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23(5):965-972
16. Strumberg D, Clark JW, Awada A, Moore MJ, Richly H, Hendlisz A, Hirte HW, Eder JP, Lenz HJ, Schwartz B (2007) Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 12(4):426-437
17. Blanchet B, Billemont B, Cramard J, Benichou AS, Chhun S, Harcouet L, Ropert S, Dauphin A, Goldwasser F, Tod M (2009) Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice. J Pharm Biomed Anal 49(4):1109-1114
18. Beal SL, Ludden T, Boeckmann A (2006) NONMEM users guide, version VI. Ellicott city; MD: GloboMax, ICON Development Solutions
19. Akaike H (1974) New look at statistical-model identification. Ieee Transactions on Automatic Control AC19:716-723
20. White DB, Walawander CA, Liu DY, Grasela TH (1992) Evaluation of hypothesis testing for comparing two populations using NONMEM analysis. J Pharmacokinet Biopharm 20(3):295-313
21. Karlsson MO, Savic RM (2007) Diagnosing model diagnostics. Clin Pharmacol Ther 82(1):17-20
22. Parke J, Holford NH, Charles BG (1999) A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. Comput Methods Programs Biomed 59(1):19-29
23. D'Argenio DZ, Schumitzky A (1997) ADAPT II user's guide: pharmacokinetic/pharmacodynamic systems analysis software. Biomedical Simulations Resource, Los Angeles
24. Zsila F, Fitos I, Bencze G, Keri G, Orfi L (2009) Determination of human serum alpha1-acid glycoprotein and albumin binding of various marketed and preclinical kinase inhibitors. Curr Med Chem 16(16):1964-1977
25. Centre for drug evaluation and research: approval package for: application number NDA 21-923: Clinical Pharmacology and biopharmaceutics review. Available from URL: http://www.accessdata.fda.gov/drugsatfda-docs/nda/ 2005/021923-s000-Nexavar-BioPharmR.pdf.25
26. Shargel L, Wu-Pong S, Yu A (2005) Applied biopharmaceutics and pharmacokinetics. 5 edn. The McGraw-Hill Companies, p 163.